Cellcolabs Raises $12M to Accelerate Technical Development And Global Expansion

Founded in 2021, Cellcolabs specializes in the industrial-scale production of GMP-certified mesenchymal stem cells (MSCs), using a protocol developed over two decades at the Karolinska Institutet. Its MSCs are supplied to university hospitals and private clients, including professional athletes and public figures.

The company operates a GMP-certified facility in Stockholm and provides an industrial-scale platform for allogeneic MSCs used in both research and clinical applications. Through collaborations with academic institutions and contract research programs, Cellcolabs supports projects spanning from preclinical studies to late-stage clinical trials.

While it does not offer direct patient treatments, a subsidiary sponsors international studies in fields such as cardiovascular prevention, musculoskeletal repair, and age-related frailty, all using MSCs produced in Sweden.

Dr Mattias Bernow, CEO of Cellcolabs, comments: "The industry is reaching an inflexion point. Scientific evidence is mounting. Regulatory pathways are opening. The demand for stem cells has never been greater. Yet scalable access remains the missing piece. The partnership with Titian Life Sciences provides Cellcolabs with both the capital and strategic footprint needed to grow internationally. Together, we are building the infrastructure that can make stem cell therapies widely available, not someday, but in our lifetime."

By 2035, Cellcolabs aims to reduce MSC costs by 90%, making advanced stem cell research and therapies more accessible worldwide.

Mattias Bernow says the stem cell industry is reaching a turning point, as stronger scientific evidence and clearer regulations are creating a surge in demand for mesenchymal stem cells (MSCs).

With the new funding, Cellcolabs plans to advance its technical development and expand globally, furthering its mission to make high-quality mesenchymal stem cells more accessible and affordable for both research and therapeutic applications.

About Cellcolabs

Cellcolabs is a Swedish biotech impact startup revolutionizing healthcare by making high-quality stem cells accessible and affordable. Through industrial-scale production and strategic collaborations, the company aims to prevent and treat diseases, accelerating global progress in regenerative medicine and scientific research.